MAR 12, 2020 6:48 PM PDT

Recent Data Accelerates Coronavirus SARS-CoV2 Drug Discovery

WRITTEN BY: Nouran Amin

Coronavirus (SARS-CoV-2) is a currently a human health crisis. It is not only highly infectious but results severe pneumonia (COVID-19) in some cases. Now, researchers by Prof. Dr. Rolf Hilgenfeld, University of Lübeck, have found an effective approach to studying the coronavirus by using high-intensity X-ray light from the Berlin synchrotron source BESSY II. They analyzed the 3D shape of the main protease (Mpro or also 3CLpro) of SARS-CoV-2. This protein plays a central role for maintaining the virus’s reproductive capability.

Learn more about COVID-19:

Since the world is scrambling to find treatments that work against the SARS-CoV-2, understanding the architecture of the protein is critical to identify specific areas of attack—thus, advancing drug discovery

"For such issues of highest relevance, we can offer fast track access to our instruments," says Dr. Manfred Weiss, who heads the Research Group Macromolecular Crystallography (MX) at HZB.

The high-intensity X-ray light from the BESSY II facility of the Helmholtz-Zentrum Berlin make the images of the 3D architecture of the protein molecules more clear.

“The 3D architecture provides concrete starting points for developing active substances or inhibitors. These drugs could dock specifically to target points of the macromolecule and impede its function,” says Rolf Hilgenfeld is an expert in the field of virology and already developed an inhibitor against the SARS-virus during the 2002/2003 SARS pandemic.

Source: Science Daily

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
SEP 29, 2020
Drug Discovery & Development
Cycling Molecules into Drug Candidates
SEP 29, 2020
Cycling Molecules into Drug Candidates
Statistics show that just 1 in 5,000 drug candidates ever makes it from the lab to the pharmacy. In a process that can t ...
OCT 01, 2020
Immunology
Immune Cells and MS: The Good, the Bad, and the Maybe
OCT 01, 2020
Immune Cells and MS: The Good, the Bad, and the Maybe
Much like electrical wires that are encased in plastic insulating sheaths, nerve cells also are also surrounded by a sim ...
OCT 12, 2020
Drug Discovery & Development
In vitro glycoengineering - Suitability for BioPharma manufacturing
OCT 12, 2020
In vitro glycoengineering - Suitability for BioPharma manufacturing
Introduction The importance of Fc glycosylation of monoclonal antibodies (mAbs) with regard to biological activity is wi ...
OCT 20, 2020
Cannabis Sciences
Should Cannabis Doses Be Standardized?
OCT 20, 2020
Should Cannabis Doses Be Standardized?
Should cannabis and its compounds such as tetrahydrocannabinol (THC), the psychoactive compound in cannabis, come in sta ...
OCT 03, 2020
Drug Discovery & Development
Treating Gut-Leakiness
OCT 03, 2020
Treating Gut-Leakiness
A drug called tofacitinib, also called Xeljanz , was found to treat permeability defects in the intestines. Tofacitinib ...
NOV 08, 2020
Neuroscience
New Way to Restore Fatty Myelin Sheaths on Nerve Cells
NOV 08, 2020
New Way to Restore Fatty Myelin Sheaths on Nerve Cells
Researchers from the F.M. Kirby Neurobiology Center in the US have discovered a new approach to restore myelin sheaths, ...
Loading Comments...